SHINE Technologies shared on X:
“We’re producing cancer-fighting isotopes, imaging and testing critical aerospace components, enabling next-gen fusion research and building toward clean energy.
Want to see where it all happens?”
To which Pat Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, added:
“I see the amazing revolution of PRECISION tumor-targeted radio therapy with these cancer fighting isotopes manufactured by Shine.
This will replace tissue damaging current radiation therapy.
The field of antibody and peptide radio-isotope oncology is about to explode, but to protect the ALC count (drop in NK and T cells from the radiation) we will need a solution! Guess what does that ?
Thank goodness there is one. IL-15 ..a T and NK cell growth factor to the rescue!
ALC matters. Pluvicto and IL15 combo trial being planned.
Unstoppable as the world of cancer therapy transforms to biologics.”
Other articles about radiation therapy on OncoDaily.